Search Results - "Schumacher, Karl-Maria" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

by Pirker, Robert, Prof, Pereira, Jose R, MD, von Pawel, Joachim, MD, Krzakowski, Maciej, Prof, Ramlau, Rodryg, MD, Park, Keunchil, Prof, de Marinis, Filippo, MD, Eberhardt, Wilfried EE, MD, Paz-Ares, Luis, MD, Störkel, Stephan, Prof, Schumacher, Karl-Maria, MD, von Heydebreck, Anja, PhD, Celik, Ilhan, Prof, O'Byrne, Kenneth J, Prof
Published in The lancet oncology (2012)

Get full text

Journal Article

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study

by Gatzemeier, Ulrich, Dr, von Pawel, Joachim, MD, Vynnychenko, Ihor, MD, Zatloukal, Petr, Prof, de Marinis, Filippo, MD, Eberhardt, Wilfried EE, MD, Paz-Ares, Luis, MD, Schumacher, Karl-Maria, MD, Goddemeier, Thomas, Dipl Stat, O'Byrne, Kenneth J, Prof, Pirker, Robert, Prof
Published in The lancet oncology (2011)

Get full text

Journal Article

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

by Le, Xiuning, Sakai, Hiroshi, Felip, Enriqueta, Veillon, Remi, Garassino, Marina Chiara, Raskin, Jo, Cortot, Alexis B, Viteri, Santiago, Mazieres, Julien, Smit, Egbert F, Thomas, Michael, Iams, Wade T, Cho, Byoung Chul, Kim, Hye Ryun, Yang, James Chih-Hsin, Chen, Yuh-Min, Patel, Jyoti D, Bestvina, Christine M, Park, Keunchil, Griesinger, Frank, Johnson, Melissa, Gottfried, Maya, Britschgi, Christian, Heymach, John, Sikoglu, Elif, Berghoff, Karin, Schumacher, Karl-Maria, Bruns, Rolf, Otto, Gordon, Paik, Paul K
Published in Clinical cancer research (15.03.2022)

Get full text

Journal Article

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study

by Sakai, Hiroshi, Morise, Masahiro, Kato, Terufumi, Matsumoto, Shingo, Sakamoto, Tomohiro, Kumagai, Toru, Tokito, Takaaki, Atagi, Shinji, Kozuki, Toshiyuki, Tanaka, Hiroshi, Chikamori, Kenichi, Shinagawa, Naofumi, Takeoka, Hiroaki, Bruns, Rolf, Straub, Josef, Schumacher, Karl Maria, Paik, Paul K
Published in Japanese journal of clinical oncology (01.08.2021)

Get full text

Journal Article

SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations

SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations

by Pudelko, Linda, Jaehrling, Frank, Reusch, Christof, Viteri, Santiago, Stroh, Christopher, Linde, Nina, Sanderson, Michael P., Musch, Doreen, Lebrun, Catherine Jorand, Keil, Marina, Esdar, Christina, Blaukat, Andree, Rosell, Rafael, Schumacher, Karl Maria, Karachaliou, Niki
Published in iScience (18.12.2020)

Get full text

Journal Article

Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusion

Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusion

by Pham, Lily C, Weller, Lauryn, Gann, Claudia N, Schumacher, Karl Maria, Vlassak, Soetkin, Swanson, Todd, Highsmith, Kaitlin, O'Brien, Barbara J, Nash, Sebnem, Aaroe, Ashley, de Groot, John F, Majd, Nazanin K
Published in The oncologist (Dayton, Ohio) (30.05.2024)

Get full text

Journal Article

PERSPECTIVE: Tepotinib + cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification ( MET amp)

PERSPECTIVE: Tepotinib + cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification ( MET amp)

by Bekaii-Saab, Tanios S., Van Cutsem, Eric, Cubillo, Antonio, Petorin-Lesens, Caroline, Rodriguez-Salas, Nuria, Raghav, Kanwal Pratap Singh, Dupuis, Olivier, López-López, Carlos, Tournigand, Christophe, Isambert, Nicolas, Abubaker, Khalid, Schumacher, Karl-Maria, Berghoff, Karin, Vlassak, Soetkin, Otto, Gordon, Tabernero, Josep
Published in Journal of clinical oncology (20.05.2021)

Get full text

Journal Article

Intracranial activity of tepotinib in patients (pts) with MET exon 14 ( MET ex14) skipping NSCLC enrolled in VISION

Intracranial activity of tepotinib in patients (pts) with MET exon 14 ( MET ex14) skipping NSCLC enrolled in VISION

by Patel, Jyoti D., Le, Xiuning, Veillon, Remi, Anderson, Ian Churchill, Bestvina, Christine M., Demedts, Ingel, Garassino, Marina Chiara, Mazieres, Julien, Morise, Masahiro, Smit, Egbert F., Eggleton, S. Peter, OBrate, Aurora, Otto, Gordon, Bruns, Rolf, Schumacher, Karl-Maria, Paik, Paul K.
Published in Journal of clinical oncology (20.05.2021)

Get full text

Journal Article

Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification ( MET amp)

Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification ( MET amp)

by Le, Xiuning, Paz-Ares, Luis G., Van Meerbeeck, Jan, Viteri, Santiago, Cabrera Galvez, Carlos, Vicente Baz, David, Kim, Young-Chul, Kang, Jin-Hyoung, Schumacher, Karl-Maria, Karachaliou, Niki, Adrian, Svenja, Bruns, Rolf, Paik, Paul K.
Published in Journal of clinical oncology (20.05.2021)

Get full text

Journal Article

INNV-21. COMPLETE RESPONSE TO ADJUVANT TEPOTINIB IN A PATIENT WITH NEWLY DIAGNOSED DISSEMINATED GLIOBLASTOMA (GBM) HARBORING MET AMPLIFICATION

INNV-21. COMPLETE RESPONSE TO ADJUVANT TEPOTINIB IN A PATIENT WITH NEWLY DIAGNOSED DISSEMINATED GLIOBLASTOMA (GBM) HARBORING MET AMPLIFICATION

by Pham, Lily, Gann, Claudia, Schumacher, Karl Maria, Vlassak, Soetkin, Swanson, Todd, Highsmith, Kaitlyn, Ou, Alexander, Clarke, Nathan, Aaroe, Ashley, Robell, Lindsay, O'Brien, Barbara, Nash, Sebnem, DeGroot, John, Majd, Nazanin
Published in Neuro-oncology (Charlottesville, Va.) (12.11.2021)

Get full text

Journal Article

SYST-06 INTRACRANIAL ACTIVITY OF TEPOTINIB IN PATIENTS WITH MET EXON 14 (METEX14) SKIPPING NSCLC ENROLLED IN VISION

SYST-06 INTRACRANIAL ACTIVITY OF TEPOTINIB IN PATIENTS WITH MET EXON 14 (METEX14) SKIPPING NSCLC ENROLLED IN VISION

by Leighl, Natasha, Bestvina, Christine, Patel, Jyoti, Le, Xiuning, Veillon, Remi, Anderson, Ian, Demedts, Ingel, Garassino, Marina Chiara, Mazières, Julien, Morise, Masahiro, Smit, Egbert, Eggleton, S Peter, O’Brate, Aurora, Otto, Gordon, Bruns, Rolf, Schumacher, Karl Maria, Paik, Paul
Published in Neuro-oncology advances (05.08.2022)

Get full text

Journal Article

GEOMETRY duo -1: A phase (Ph) Ib/II, multicenter trial of oral cMET inhibitor capmatinib (INC280) ± erlotinib vs platinum + pemetrexed in adult patients (pts) with epidermal growth factor receptor (EGFR)-mutated, cMET-amplified, locally advanced/metastatic non-small cell lung cancer (NSCLC) with acquired resistance to prior EGFR tyrosine kinase inhibitor (TKI) therapy

GEOMETRY duo -1: A phase (Ph) Ib/II, multicenter trial of oral cMET inhibitor capmatinib (INC280) ± erlotinib vs platinum + pemetrexed in adult patients (pts) with epidermal growth factor receptor (EGFR)-mutated, cMET-amplified, locally advanced/metastatic non-small cell lung cancer (NSCLC) with acquired resistance to prior EGFR tyrosine kinase inhibitor (TKI) therapy

by Smit, Egbert F., Kopp, Hans-Georg, Kim, Dong-Wan, Tortora, Giampaolo, Spira, Alexander I., Berruti, Alfredo, Lee, Dae Ho, Reguart, Noemi, Rybkin, Igor I., Akimov, Mikhail, Schumacher, Karl Maria, Upalawanna, Allison, Xu, Cindy, Squires, Matthew, Tan, Daniel Shao-Weng
Published in Journal of clinical oncology (20.05.2016)

Get full text

Journal Article

TRLS-03. Intracranial activity of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC enrolled in VISION

TRLS-03. Intracranial activity of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC enrolled in VISION

by Bestvina, Christine M, Le, Xiuning, Veillon, Remi, Anderson, Ian, Patel, Jyoti, Demedts, Ingel, Garassino, Marina, Mazières, Julien, Morise, Masahiro, Smit, Egbert, Eggleton, S Peter, O’Brate, Aurora, Otto, Gordon, Bruns, Rolf, Schumacher, Karl Maria, Paik, Paul
Published in Neuro-oncology advances (09.08.2021)

Get full text

Journal Article

Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab

Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab

by Cao, Z, Alexander, Pinzon-Ortiz, Maria, Chen, Yan, Li, Xiaoyan, Beltran, Pedro J., Gansert, Jennifer L., Peters, Malte, Schlegel, Robert, Schumacher, Karl Maria, Huang, Alan
Published in Journal of clinical oncology (20.05.2013)

Get full text

Journal Article

Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors

Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors

by Kefford, Richard, Miller, Wilson H, Tan, Daniel Shao-Weng, Sullivan, Ryan J., Long, Georgina, Dienstmann, Rodrigo, Tai, Wai Meng David, Flaherty, Keith, Stutvoet, Simone, Schumacher, Karl Maria, Wandel, Simon, De Parseval, Laure A., Tabernero, Josep
Published in Journal of clinical oncology (20.05.2013)

Get full text

Journal Article

COMBINATION THERAPY OF INHIBITORS FOR IGF1R AND PI3K

COMBINATION THERAPY OF INHIBITORS FOR IGF1R AND PI3K

by PETERS MALTE, SCHUMACHER KARL MARIA, CHANG DAVID DONG EUN, HUANG XIZHONG, CAO ZHU ALEXANDER, GANSERT JENNIFER LORRAINE
Year of Publication 05.08.2015

Get full text

Patent

COMBINATION THERAPY OF INHIBITORS FOR IGF1R AND PI3K

COMBINATION THERAPY OF INHIBITORS FOR IGF1R AND PI3K

by HUANG, XIZHONG, CAO, ZHU ALEXANDER, PETERS, MALTE, CHANG, DAVID DONG EUN, GANSERT, JENNIFER LORRAINE, SCHUMACHER, KARL MARIA
Year of Publication 27.05.2015

Get full text

Patent

Combination therapy of a mek inhibitor and igf1r inhibitor

Combination therapy of a mek inhibitor and igf1r inhibitor

by PETERS MALTE, SCHUMACHER KARL MARIA, CHANG DAVID DONG EUN, HUANG XIZHONG, CAO ZHU ALEXANDER, GANSERT JENNIFER LORRAINE
Year of Publication 01.04.2015

Get full text

Patent

Combination therapy

Combination therapy

by PETERS MALTE, SCHUMACHER KARL MARIA, CHANG DAVID DONG EUN, HUANG XIZHONG, CAO ZHU ALEXANDER, GANSERT JENNIFER LORRAINE
Year of Publication 17.03.2015

Get full text

Patent

Combination therapy of inhibitors for IGF1 R and PI3K

Combination therapy of inhibitors for IGF1 R and PI3K

by HUANG, XIZHONG, CAO, ZHU ALEXANDER, PETERS, MALTE, CHANG, DAVID DONG EUN, GANSERT, JENNIFER LORRAINE, SCHUMACHER, KARL MARIA
Year of Publication 05.02.2015

Get full text

Patent